Remdesivir cuts death risk by 62% in coronavirus patients, new study shows

pharmafile | July 13, 2020 | News story | Sales and Marketing COVID-19, coronavirus 

Gilead’s remdesivir reduced the risk of death in 62% of severe COVID-19 patients, according to a new study.

The company released a statement which said: “The analysis demonstrated that remdesivir treatment was associated with the significantly improved clinical recovery and a 62 percent reduction in the risk of mortality compared to standard of care.” 

This latest Phase 3 SIMPLE trial included 312 patients being treated with Gilead’s drug compared with 818 being in the standard care group with both groups showing a similar severity of the virus.

74.4% of the remdesivir group recovered by day 14, versus 59% of the standard care group. It also showed that 7.6% of the group being treated with the drug died compared to 12.5% of the care group meaning it cut the death risk by 62%. Gilead also stated that its compassionate use program demonstrated that 83% of 77 pediatric patients and 92% of 86 pregnant and postpartum women recovered from the virus by day 28.

South Korea has started to provide the treatment free of charge through the Ministry of Food and Drug Safety’s special import program. However, from August patients will have to pay the medical costs.

Conor Kavanagh

Related Content

ACM Biolabs shares positive results from phase 1 SARS-CoV-2 booster vaccine trial

ACM Biolabs has announced positive topline results from its phase 1 trial of ACM-001, an …

The NIH’s RECOVER initiative could lead to the first official treatment for long COVID-19

As of 31 July 2023, The National Institutes of Health (NIH) launched the first trials …


Moderna files for FDA authorisation for updated COVID-19 vaccine

Biotechnology company Moderna has announced that it has completed submission of a regulatory application to …

Latest content